Compare Fox Corp Class A (FOXA) vs Johnson & Johnson (JNJ) Price & Performance

Fox Corporation (FOXA) trades at $62.68, down slightly by 0.03% on the day. The stock shows a bullish technical signal with strong earnings beats in recent quarters, including Q2 2026 EPS of $1.79 versus $1.44 expected. Revenue grew to $16.30 billion in 2025, with a net income margin of 13.88%. Key developments include the pending $22 billion acquisition of Roku, which is under DOJ review, and a dividend payment scheduled for September 2026.

The outlook is positive with a consensus price target of $72.00, implying 15% upside. Strengths include robust cash flow and analyst support, but risks involve regulatory scrutiny of the Roku deal and a projected decline in 2026 net income. The stock presents a value opportunity with a P/E of 16.55, though investors should monitor deal progression and earnings sustainability.

Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.

JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.